文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低剂量肝素或低分子肝素持续抗凝治疗对急性呼吸窘迫综合征患者预后影响的Meta分析

[Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论Meta分析纳入14项RCT共894例ARDS患者,低剂量肝素或低分子肝素持续抗凝可降低28天病死率(RR=0.54,95%CI 0.38-0.76,P=0.000 4)。

该Meta分析系统评价低剂量肝素和低分子肝素对急性呼吸窘迫综合征(ARDS)患者疗效及预后的影响,检索万方、维普、中国知网、SinoMed、PubMed、Embase和Cochrane图书馆等中英文数据库,纳入1999年7月至2020年6月发表的随机对照试验(RCT)。试验组在常规治疗基础上给予肝素5-10 U×kg-1×h-1持续抗凝,或低分子肝素2 500-5 000 U皮下注射、每12小时1次、疗程7天;对照组给予常规治疗。共纳入14篇中文文献、894例患者(试验组454例,对照组440例)。Meta分析显示试验组28天病死率显著低于对照组(RR=0.54,95%CI 0.38-0.76,P=0.000 4),7天动脉血氧饱和度(SaO2)显著升高,APACHEⅡ评分、肺损伤评分、呼吸频率、ICU停留时间和机械通气时间均降低,IL-6、TNF-α、CRP水平显著降低,而活化部分凝血活酶时间(APTT)和凝血酶原时间(PT)无显著差异。作者结论认为低剂量肝素和低分子肝素持续抗凝治疗可改善ARDS患者预后、降低病死率。

要点

  • 纳入14项RCT共894例ARDS患者(试验组454例、对照组440例),试验组28天病死率显著低于对照组(RR=0.54,95%CI 0.38-0.76,P=0.000 4)。
  • 7天SaO2显著升高:肝素组MD=48.27(95%CI 29.95-66.59,P<0.000 01),低分子肝素组MD=56.67(95%CI 41.22-71.13,P<0.000 01)。
  • 7天APACHEⅡ评分(MD=-4.28,95%CI -5.15至-3.42,P<0.000 01)、肺损伤评分(MD=-1.19,95%CI -1.35至-1.03,P<0.000 01)、呼吸频率(MD=-4.76,95%CI -6.26至-3.26,P<0.000 01)均显著低于对照组。
  • ICU停留时间(MD=-4.85,95%CI -6.94至-2.76,P<0.000 01)和机械通气时间(MD=-2.93,95%CI -3.34至-2.52,P<0.000 01)均低于对照组。
  • 7天IL-6(MD=-38.50,95%CI -59.01至-17.99,P<0.000 01)、TNF-α(MD=-16.24,95%CI -31.11至-1.38,P<0.000 01)、CRP(MD=-5.5,95%CI -6.47至-4.27,P<0.000 01)显著降低,而APTT(MD=-0.55,95%CI -1.61至0.51,P=0.27)和PT(MD=-0.41,95%CI

适用人群与场景

  • 急性呼吸窘迫综合征(ARDS)患者,纳入14项随机对照试验共894例,其中试验组454例、对照组440例。

处置流程与药物剂量

  • 试验组在常规治疗基础上给予肝素5-10 U×kg-1×h-1持续抗凝,或低分子肝素2 500-5 000 U皮下注射、每12小时1次、疗程7天。
  • 对照组给予常规治疗。

研究设计与关键结果

  • Meta分析纳入14篇中文文献、共894例ARDS患者(试验组454例,对照组440例),试验组在常规治疗基础上接受肝素5-10 U×kg-1×h-1或低分子肝素2 500-5 000 U皮下注射每12小时1次、疗程7天。
  • 试验组28天病死率显著低于对照组(RR=0.54,95%CI 0.38-0.76,P=0.000 4)。
  • 7天SaO2显著升高:肝素组MD=48.27(95%CI 29.95-66.59,P<0.000 01),低分子肝素组MD=56.67(95%CI 41.22-71.13,P<0.000 01)。
  • 7天APACHEⅡ评分(MD=-4.28,95%CI -5.15至-3.42,P<0.000 01)、肺损伤评分(MD=-1.19,95%CI -1.35至-1.03,P<0.000 01)、呼吸频率(MD=-4.76,95%CI -6.26至-3.26,P<0.000 01)均显著低于对照组。
  • ICU停留时间(MD=-4.85,95%CI -6.94至-2.76,P<0.000 01)和机械通气时间(MD=-2.93,95%CI -3.34至-2.52,P<0.000 01)均低于对照组。
  • 7天IL-6(MD=-38.50,95%CI -59.01至-17.99,P<0.000 01)、TNF-α(MD=-16.24,95%CI -31.11至-1.38,P<0.000 01)、CRP(MD=-5.5,95%CI -6.47至-4.27,P<0.000 01)显著低于对照组。
  • 7天APTT(MD=-0.55,95%CI -1.61至0.51,P=0.27)和PT(MD=-0.41,95%CI -1.48至0.66,P=0.45)两组无显著差异。
  • 对异质性较高的指标逐一剔除研究后再次行Meta分析,总效应值无明显改变,提示结果较稳健;对纳入文献超过10篇的指标行漏斗图分析,结果显示文献存在发表偏倚,但偏倚较小。

证据类型、等级与局限

  • 证据类型:Meta分析,纳入14项随机对照试验(RCT)。
  • 文献质量按Cochrane 5.1标准评价,采用敏感性分析检验结果稳定性,采用漏斗图分析发表偏倚。
  • 局限性:漏斗图分析显示文献存在发表偏倚,但偏倚较小;纳入文献均为中文文献。

对床旁实践的改变

  • 作者结论认为,低剂量肝素和低分子肝素持续抗凝治疗可改善ARDS患者预后、降低病死率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The effects of low-dose heparin and low molecular weight heparin on the efficacy and prognosis of patients with acute respiratory distress syndrome (ARDS) were systematically evaluated.

METHODS: Chinese and English databases such as Wanfang data, VIP database, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Service system (SinoMed), American National Medical Library database (PubMed), Netherlands Medical Abstracts database (Embase) and Cochrane library database were searched for the randomized controlled trials (RCTs) of heparin or low molecular weight heparin in the treatment of ARDS. The search time is from July 1999 to June 2020. The control group was given routine treatment, while the experimental group was given heparin 5-10 U×kg-1×h-1, or low molecular heparin subcutaneous injected 2 500-5 000 U once every 12 hours for 7 days on the basis of the routine treatment. The main outcome were 28-day mortality, arterial oxygen saturation (SaO2), acute physiology and chronic health evaluation II (APACHE II), length of stay in (intensive care unit) ICU and mechanical ventilation time, and the secondary outcome indexes were C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), lung injury score, respiratory frequency, activated partial thromboplastin time (APTT) and prothrombin time (PT) after 7 days' treatment. The two researchers collected data and evaluated the quality of the literature according to the Cochrane 5.1. The stability of the Meta-analysis results was tested by sensitivity analysis, and the publication bias was included in the funnel chart analysis.

RESULTS: Fourteen Chinese literatures were included, with a total of 894 cases, including 454 cases in the experimental group and 440 cases in the control group. The results of Meta-analysis showed that the 28-day fatality rate in the experimental group was significantly lower than that in the control group [relative risk (RR) = 0.54, 95% confidence interval (95%CI) was 0.38-0.76, P = 0.000 4], and 7-day SaO2 significantly increased [heparin: mean difference (MD) = 48.27, 95%CI was 29.95-66.59, P < 0.000 01]. Low molecular weight heparin: MD = 56.67, 95%CI was 41.22-71.13, P < 0.000 01]. Compared with the control group, the APACHE II score (MD = -4.28, 95%CI was -5.15 to -3.42, P < 0.000 01), the lung injury score (MD = -1.19, 95%CI was -1.35 to -1.03, P < 0.000 01) and the respiratory rate (MD = -4.76, 95%CI was -6.26 to -3.26, P < 0.000 01) in the experimental group were significantly lower than those in the control group after 7 days' treatment. The time of staying in ICU (MD = -4.85, 95%CI was -6.94 to -2.76, P < 0.000 01) and the time of mechanical ventilation (MD = -2.93, 95%CI was -3.34 to -2.52, P < 0.000 01) in the experimental group were lower than those in the control group. After 7 days' treatment, the levels of IL-6 (MD = -38.50, 95%CI was -59.01 to -17.99, P < 0.000 01), TNF-α (MD = -16.24, 95%CI was -31.11 to -1.38, P < 0.000 01) and CRP (MD = -5.5, 95%CI was -6.47 to -4.27, P < 0.000 01) were significantly lower in the experimental group than those in the control group. However, after 7 days' treatment, there were no significant differences in APTT (MD = -0.55, 95%CI was -1.61 to 0.51, P = 0.27) or PT (MD = -0.41, 95%CI was -1.48 to 0.66, P = 0.45). For the indicators with high heterogeneity, Meta-analysis was carried out again by excluding any study, and the overall effect value did not change significantly, suggesting that the results were relatively robust. Funnel chart analysis was carried out on the indexes with more than 10 articles included in the literature. The results showed that the literature had publication bias, but the bias was small.

CONCLUSIONS: Continuous anticoagulation therapy with low dose heparin and low molecular weight heparin can improve the prognosis and reduce the mortality of patients with ARDS.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zheng X, Shen F, Li X, et al. [Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33541501. doi:10.3760/cma.j.cn121430-20200928-00652

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。